Scientists are increasingly focused on retatrutide, a innovative drug created by Eli Lilly, as a possible step in weight management. Unlike many previous approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, hormones that influence satiety and blood glucose regulation .